How can we predict and reduce the risk of thrombosis in a patient with PV?

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MPN Hub spoke to Gabriela Hobbs, Massachusetts General Hospital, Boston, US. We asked: How can we predict and reduce the risk of thrombosis in a patient with polycythemia vera (PV)?

Patients with PV are at an increased risk of experiencing thrombotic complications, and cardiovascular events are the leading cause of death in these patients. Here, Gabriela Hobbs outlines the key risk factors and some of the driving biological processes for thrombosis in patients with PV.

A number of factors determine a patient's risk of thrombosis, including age and lifestyle factors. Here, Gabriela Hobbs describes how to manage patients on an individual basis to reduce the risk of thrombosis.